8 new development(s) in neoantigen vaccines today.
by EMMA KOPPELMAN | The National News Desk (TNND) — A personalized cancer vaccine reduced the risk of melanoma returning or patients dying by 42% when given with a standard immunotherapy drug, according to late-stage trial results released Thursday by drugmakers Moderna and Merck…
Leaked confidential data. A major stock sell-off. Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results …
A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a major breakthrough after it reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage clinical trial. Dr. Robert Vonderheide, director of Penn Medic…
The vaccine was custom-brewed for each patient to match their tumor. A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. The vac…
Our scientists pursue every aspect of cancer research—from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more. Our highly-specialized educational programs shape leaders to be at the forefront of cancer ca…
A personalized cancer vaccine could be available as soon as 2027. Here’s what we know Fast Company
Test your knowledge with our new weekday mini crossword Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and aut…
Relevant work from earlier we're still surfacing — not today's news.